This systematic review and meta-analysis examined the use of Rho-kinase inhibitors for patients with uveitic glaucoma or ocular hypertension secondary to uveitis. The analysis included data from 383 participants involving 256 eyes. Researchers looked at how these medications affected eye pressure and surgical outcomes over three and 12 months.
The study found a statistically significant reduction in eye pressure at three months. This effect was sustained at 12 months. The medications showed a favorable safety profile overall. Common side effects included conjunctival hyperemia, ocular pain, and blurred vision. No serious adverse events were reported.
However, some studies reported outcomes per eye while others reported outcomes per patient. Two studies had a low risk of bias, four raised some concerns, and five were at high risk of bias. Further clinical trials are needed to compare different ROCK inhibitors and assess their long-term safety and effectiveness in different populations.